Sensei Biotherapeutics (SNSE) AI Stock Analysis

• Market Cap: $11.04M
• Dividend Yield: N/A
• Average Volume (3M): 38.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.34
• Revenue Growth: N/A
• EPS Growth: 9.63%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.62
• Shares Outstanding: 1,261,290
• 10 Day Avg. Volume: 109,584
• 30 Day Avg. Volume: 38,927
• PEG Ratio: 4.98
• Price to Book (P/B): 6.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -9.92
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: -0.55
• Enterprise Value/Gross Profit: -13.03
• Enterprise Value/Ebitda: -0.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $9.00 ▼(-21.19% Downside)

The score is held down primarily by weak fundamentals—minimal/negative revenue, persistent losses, and ongoing cash burn with a shrinking equity base—implying continued financing risk. Technicals are a relative bright spot with price trading above key moving averages and positive MACD, but valuation remains constrained by negative earnings, and corporate events add uncertainty due to program discontinuation and strategic review.

Positive Factors

Low leverage / conservative debt profile

Sensei's very low debt-to-equity (~0.09) reduces interest burden and financial distress risk, giving management more flexibility to finance R&D through equity or partnerships. This conservatism supports runway extension and strategic options over the next several months.

Executive retention and alignment

Amended retention and bonus agreements for the CEO and SVP Finance increase leadership continuity during a critical period. Stable senior management reduces execution risk around clinical programs and strategic decisions, improving odds of orderly program prioritization and partner negotiations.

Immuno-oncology, antibody-based platform focus

Sensei's platform focus on engineered antibody immunotherapies aligns with enduring structural demand in oncology. A platform approach can generate multiple candidates and partnering opportunities, supporting longer-term upside if clinical traction or alliances occur.

Negative Factors

Sustained cash burn and weak cash generation

Persistent negative OCF/FCF (~-$22.4M TTM) shows operations consume cash rather than generate it. This structural cash burn necessitates external financing or dilutive capital raises, which can erode shareholder value and constrain long-term program funding and development timelines.

Minimal commercial revenue and recurring losses

With effectively no revenue and recurring sizable net losses, Sensei remains commercially unproven and reliant on capital markets. Continued negative gross profit and losses mean limited internal funding for R&D, heightening financing and dilution risk over the medium term.

Program discontinuation and strategic review

Halting a program and launching a strategic review with headcount cuts signals material uncertainty about pipeline priorities and execution. This raises the risk of asset write-downs, delays to clinical timelines, and reduced attractiveness to partners or acquirers in the near to medium term.

Sensei Biotherapeutics Business Overview & Revenue Model

Company Description

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

How the Company Makes Money

Sensei Biotherapeutics makes money primarily through the development and potential commercialization of its proprietary immunotherapy products. The company's revenue model is centered around advancing its product candidates through clinical trials, with the ultimate goal of gaining regulatory approval for commercialization. Key revenue streams may include licensing agreements, collaborations, and partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales of their developed therapies. Additionally, Sensei may secure funding through grants and research collaborations that support its R&D efforts. However, as a clinical-stage company, Sensei is primarily focused on research and development activities and may not yet have significant product sales revenue.

Sensei Biotherapeutics Financial Statement Overview

Summary

Financial profile is weak: revenue has been effectively zero/negative with persistently negative gross profit, recurring sizable net losses (TTM net loss ~$24.1M), and consistently negative operating/free cash flow (TTM OCF/FCF ~-$22.4M). Low leverage is a positive (TTM debt-to-equity ~0.09), but equity has declined sharply (to ~$23.0M TTM), reinforcing funding and dilution risk.

Income Statement

Financial performance remains weak. Annual revenue was effectively zero from 2020–2024, and TTM (Trailing-Twelve-Months) revenue is negative, alongside persistently negative gross profit—suggesting the business is still in a heavy R&D/clinical-stage phase with limited commercial traction. Losses are sizable and recurring (TTM net loss of ~$24.1M; annual net losses of ~$30–49M in prior years). A modest positive is that losses have narrowed versus the 2022 peak, but profitability and margin profile remain highly challenged.

Balance Sheet

Balance sheet looks relatively conservative on leverage, with low debt levels versus equity (TTM debt-to-equity ~0.09; similar range across recent years). However, equity has declined materially over time (from ~ $146.5M in 2021 to ~ $23.0M TTM), consistent with ongoing losses and cash burn. Returns on equity are deeply negative (TTM ~-0.80), highlighting continued value erosion despite manageable leverage.

Cash Flow

Cash generation is structurally weak, with consistently negative operating and free cash flow (TTM operating cash flow ~-$22.4M; TTM free cash flow ~-$22.4M). Free cash flow has not shown sustained improvement (TTM free cash flow growth is sharply negative), implying ongoing funding needs. While free cash flow tracks net loss closely (free cash flow to net income ~1.0), this mainly indicates losses are cash-based rather than a result of accounting non-cash items—reinforcing the cash burn risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-4.85M	0.00	0.00	0.00	0.00	0.00
Gross Profit	-206.00K	-551.00K	-571.00K	-1.81M	-685.00K	-209.00K
EBITDA	-23.85M	-29.52M	-33.39M	-46.56M	-35.44M	-18.20M
Net Income	-24.14M	-30.16M	-34.10M	-48.59M	-36.79M	-20.10M
Balance Sheet
Total Assets	27.59M	45.36M	74.37M	118.38M	153.22M	21.43M
Cash, Cash Equivalents and Short-Term Investments	25.04M	41.34M	65.76M	107.12M	147.62M	16.60M
Total Debt	2.02M	3.85M	6.21M	8.03M	2.35M	685.00K
Total Liabilities	4.58M	6.97M	9.48M	14.97M	6.71M	5.54M
Stockholders Equity	23.01M	38.39M	64.89M	103.41M	146.51M	15.89M
Cash Flow
Free Cash Flow	-22.40M	-24.82M	-32.20M	-39.35M	-32.28M	-18.91M
Operating Cash Flow	-22.38M	-24.67M	-32.02M	-39.03M	-30.26M	-17.70M
Investing Cash Flow	14.54M	22.44M	38.41M	49.95M	-143.12M	-1.40M
Financing Cash Flow	-728.00K	-787.00K	-11.17M	-287.00K	163.94M	35.45M

Sensei Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.42
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Negative. The current price of 11.42 is above the 20-day moving average (MA) of 10.30, above the 50-day MA of 9.56, and above the 200-day MA of 8.71, indicating a neutral trend. The MACD of -0.24 indicates Positive momentum. The RSI at 41.99 is Neutral, neither overbought nor oversold. The STOCH value of 15.88 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNSE.

Sensei Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLRB	53 Neutral	$12.68M	-0.27	-145.42%	―	―	79.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNSE	51 Neutral	$11.04M	-0.42	-67.47%	―	―	9.63%
BOLT	48 Neutral	$10.52M	-0.24	-81.97%	―	-46.88%	34.83%
COCP	45 Neutral	$13.23M	-0.92	-94.94%	―	―	49.10%
BRTX	44 Neutral	$9.14M	-0.67	-207.73%	―	1.70%	-111.67%

Sensei Biotherapeutics Corporate Events

Sensei Biotherapeutics Updates Executive Retention and Compensation Agreements

On December 22, 2025, Sensei Biotherapeutics, Inc. entered into amended retention agreements with President and Principal Executive Officer Christopher Gerry and Senior Vice President of Finance and Principal Finance and Accounting Officer Josiah Craver, revising key compensatory terms in their employment arrangements. Effective November 14, 2025, the company set Gerry’s annual base salary at $425,000 and Craver’s at $400,000 and made both executives eligible for an annual target bonus equal to 40% of base salary beginning with the 2026 fiscal year; it also established a structure of retention bonuses tied to continued employment into early 2026 or to certain termination scenarios, with enhanced benefits if they are terminated without cause or resign for good reason outside the context of a change in control, contingent on signing a separation and release agreement. The changes strengthen management’s financial incentives to remain with the company during a critical period, potentially providing greater leadership stability and signaling a focus on executive retention to investors and other stakeholders.

The most recent analyst rating on (SNSE) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Sensei Biotherapeutics stock, see the SNSE Stock Forecast page.